Released: Tuesday 19th May 2015

 Glasgow, UK, Sistemic Limited (Sistemic), the miRNA profiling company with headquarters in Glasgow, Scotland, announced today the expansion of its granted patent portfolio in both the European Union and in the USA.

Following from the grant of European Patent number 2387617 late last year, the US Patent and Trade Mark Office (USPTO) has now notified Sistemic of its intent to grant a patent from its U.S. Patent Application No. 13/145,208. This patent grant expands Sistemic’s patent estate for core technologies in stem cell characterisation, potency assay development and quality control of stem cell products.

Sistemic’s technology is based on the phenotypic understanding of cells possible through miRNA profile analysis. The company is pursuing patents covering the application of its technology in cell therapy and drug discovery and is advancing its patent portfolio in most major world markets including Europe, USA, Japan and a number of other territories.

Jim Reid, Chairman and CEO, Sistemic stated that “continued expansion of our granted patent portfolio in both of the company’s main markets of Europe and USA demonstrates the unique position of the company’s technology and confirms the development strategy being pursued by the company in bringing novel miRNA-based technologies to enhance the development of cell therapies. Advanced therapies hold great promise for a wide range of currently untreatable diseases but without the necessary characterisation and quality control tools the undoubted promise of these novel treatments will not be fully delivered. Sistemic’s patented technologies will enhance the potential for the broader adoption of the therapies and successful treatment of a wide range of diseases.”  
Dr Donald Dunbar, Head of Bioinformatics and Chairman of the IP Committee stated that “It is vitally important to a company like Sistemic that we protect our key technologies. The expansion in our patent portfolio is an essential step in bringing our ground-breaking technologies and products to a broader audience.”

About Sistemic Ltd
Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™.
More information is available at http://www.sistemic.co.uk